Revel is an excellent addition to the arsenal of any scientist who wants to drastically reduce the number of false positives and negatives in their primary screen.
SAN DIEGO (PRWEB) January 28, 2019
Fragment-based lead discovery (FBLD) involves biophysical screening of proteins against libraries of low molecular weight compounds. In this early stage, false positives can be problematic due to high levels of solvents and nonspecific hydrophobic binding. At the same time, it is vital that screening techniques are highly sensitive to detect weak interactions. Nanomed, leading producer of graphene biosensors for pharmaceutical and biotherapeutics research, announces the launch of the Early Access Program for Revel, the first high-throughput direct measurement platform for fragments and small molecules using orthogonal Field Effect Biosensing (FEB) technology.
“Until now, FBLD researchers have had to balance throughput, sensitivity and protein consumption using multiple techniques to cross-check results,” says Nanomed CEO, Ross Bundy. “Revel is on par with ligand-observed NMR in sensitivity and throughput, while using much less protein, even less than thermal shift assays. It is an excellent addition to the arsenal of any scientist who wants to drastically reduce the number of false positives and negatives in their primary screen.”
Revel is a 24-channel direct binding system that is fully automated with a 48-hour walkaway run time, designed to be used with the Nimbus HD liquid handler by Hamilton Robotics. Easy-to-use, built-in software acquires and analyzes data in real time, enabling results for 576 interactions in a day, including analysis. The platform measures up to 10 mM concentrations, ensuring accurate detection of low affinity binding interactions. Revel uses orthogonal FEB technology, a breakthrough electrical sensing technique that is unaffected by optical impediments such as solvents and significantly reduces nonspecific binding.
“We are opening the Revel Early Access Program to experienced researchers with active FBLD screening programs for performance studies and valuable product testing feedback,” continues Mr. Bundy. “Working closely with these development partners is the next step in our vision of bringing accurate, quantitative results to drug discovery pipelines without sacrificing cost or time.”
Nanomed will present Revel at Booth 213 at the 2019 SLAS Conference from February 4 through 6 in Washington, D.C.
Nanomed is a life science company based in San Diego, California. As the world’s leading manufacturer and developer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.